indazoles has been researched along with Myelodysplastic Syndromes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Cearbhaill, RE | 1 |
| Bohannan, Z; Cable, L; Calvo, MC; Garcia-Manero, G; Hogeland, G; Jabbour, E; Kantarjian, H; Khoury, HJ; Komrokji, R; Lancet, J; List, A; Maloney, L; Ptaszynski, M; Rush, S; Winski, SL | 1 |
| Bohannan, ZS; Gañán-Gómez, I; Garcia-Manero, G | 1 |
| Akutagawa, J; Braun, BS; Chang, T; Cottonham, CL; Dail, M; Epstein, I; Friedman, LS; Huang, TQ; Quirindongo-Crespo, M; Sampath, D; Slusher, BS | 1 |
| Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y | 1 |
| Bellamy, WT; Beran, M; Bycott, P; Estrov, Z; Giles, FJ; List, AF; O'Brien, SM; Pithavala, Y; Ravandi, F; Reich, SD; Steinfeldt, H; Verstovsek, S; Yee, KW | 1 |
2 trial(s) available for indazoles and Myelodysplastic Syndromes
| Article | Year |
|---|---|
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle Aged; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, TIE-2; Treatment Outcome; Urea | 2015 |
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
4 other study(ies) available for indazoles and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
p38 MAPK in MDS.
Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Urea | 2015 |
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Topics: Animals; Heterocyclic Compounds, 3-Ring; Indazoles; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; MAP Kinase Signaling System; Mice; Myelodysplastic Syndromes; Myeloproliferative Disorders; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Sulfonamides | 2016 |
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Proportional Hazards Models; Receptor, TIE-2; Urea | 2016 |